Dx & Vx Co., Ltd. (KOSDAQ:180400)

Market Cap	94.11B
Revenue (ttm)	33.95B
Net Income (ttm)	-47.03B
Shares Out	49.22M
EPS (ttm)	-1,309.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	257,140
Average Volume	1,108,636
Open	1,902.00
Previous Close	1,931.00
Day's Range	1,832.00 - 1,930.00
52-Week Range	1,309.00 - 5,610.00
Beta	-0.00
RSI	54.41
Earnings Date	Mar 21, 2025

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Employees: 112
• Stock Exchange: KOSDAQ
• Ticker Symbol: 180400

Financial Performance

In 2023, Dx & Vx's revenue was 46.75 billion, an increase of 45.24% compared to the previous year's 32.18 billion. Losses were -27.48 billion, 3425.0% more than in 2022.